FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136929667> ?p ?o ?g. }

• W3136929667 endingPage "S465" @default.
• W3136929667 startingPage "S465" @default.
• W3136929667 abstract "Purpose The REPLACE study showed that switching to riociguat (rio) can benefit pulmonary arterial hypertension (PAH) patients treated with phosphodiesterase type 5 inhibitors (PDE5i) but still at intermediate risk. Improvements to lower risk status with rio versus PDE5i were seen with all three risk assessment tools analyzed, although the difference was not statistically significant with the modified REVEAL risk score (mRRS). Here, we report changes in the components of the mRRS, COMPERA, and FPHN non-invasive risk assessment tools, and a post hoc analysis of RRS Lite 2 in REPLACE. Methods Individual components of mRRS, COMPERA, and FPHN non-invasive assessment tools, and RRS Lite 2 risk scores and risk strata were calculated for the rio group (n=111) and PDE5i group (n=113) at REPLACE baseline and Week 24. WHO/NYHA functional class (FC), 6MWD, and NT-proBNP were components of all risk scores. Vital signs (systolic blood pressure [SBP] and heart rate [HR]) and renal insufficiency were additional components for mRRS and RRS Lite 2. PAH etiology and demographics were also components of mRRS. Results For mRRS, COMPERA, and FPHN, 44% of patients in the rio group vs 23% in the PDE5i group improved their WHO/NYHA FC component score at Week 24. Similar results were found for the 6MWD component (1 point removed from mRRS: rio 41% vs PDE5i 27%; COMPERA grade 1/FPHN low risk at Week 24: rio 37% vs PDE5i 27%). The incidences of lowest-risk NT-proBNP component scores at Week 24 were rio 41% vs PDE5i 40% for mRRS, rio 21% vs PDE5i 12% for COMPERA, and rio 41% vs PDE5i 40% for FPHN. At baseline, mRRS vital sign scores were similar between the two groups. At Week 24, more patients in the rio group (50%) versus the PDE5i group (36%) had 1−2 points added to their mRRS score due to SBP 96 bpm. The overall result was similar for the mRRS and the RRS Lite 2. With RRS Lite 2, the proportion of patients achieving a low-risk stratum from baseline to Week 24 was 41% to 61% for rio and 37% to 50% for PDE5i. Conclusion Risk assessment tools showed similar trends in shared components between treatment groups at baseline and Week 24. Results with RRS Lite 2 were similar to mRRS. Differences in discrimination of the risk sores, weighting of components, and differences in the vital signs component of mRRS could explain between score differences at baseline and Week 24 in REPLACE. SBP and HR will be individually analyzed in future." @default.
• W3136929667 created "2021-03-29" @default.
• W3136929667 creator A5006888214 @default.
• W3136929667 creator A5013077384 @default.
• W3136929667 creator A5016773092 @default.
• W3136929667 creator A5024507792 @default.
• W3136929667 creator A5027745611 @default.
• W3136929667 creator A5031279303 @default.
• W3136929667 creator A5031477165 @default.
• W3136929667 creator A5047521532 @default.
• W3136929667 creator A5058197659 @default.
• W3136929667 creator A5063639184 @default.
• W3136929667 date "2021-04-01" @default.
• W3136929667 modified "2023-10-06" @default.
• W3136929667 title "Analysis of Risk Assessment Tools in the REPLACE Study" @default.
• W3136929667 doi "https://doi.org/10.1016/j.healun.2021.01.1289" @default.
• W3136929667 hasPublicationYear "2021" @default.
• W3136929667 type Work @default.
• W3136929667 sameAs 3136929667 @default.
• W3136929667 citedByCount "0" @default.
• W3136929667 crossrefType "journal-article" @default.
• W3136929667 hasAuthorship W3136929667A5006888214 @default.
• W3136929667 hasAuthorship W3136929667A5013077384 @default.
• W3136929667 hasAuthorship W3136929667A5016773092 @default.
• W3136929667 hasAuthorship W3136929667A5024507792 @default.
• W3136929667 hasAuthorship W3136929667A5027745611 @default.
• W3136929667 hasAuthorship W3136929667A5031279303 @default.
• W3136929667 hasAuthorship W3136929667A5031477165 @default.
• W3136929667 hasAuthorship W3136929667A5047521532 @default.
• W3136929667 hasAuthorship W3136929667A5058197659 @default.
• W3136929667 hasAuthorship W3136929667A5063639184 @default.
• W3136929667 hasBestOaLocation W31369296671 @default.
• W3136929667 hasConcept C112930515 @default.
• W3136929667 hasConcept C12174686 @default.
• W3136929667 hasConcept C38652104 @default.
• W3136929667 hasConcept C41008148 @default.
• W3136929667 hasConcept C71924100 @default.
• W3136929667 hasConceptScore W3136929667C112930515 @default.
• W3136929667 hasConceptScore W3136929667C12174686 @default.
• W3136929667 hasConceptScore W3136929667C38652104 @default.
• W3136929667 hasConceptScore W3136929667C41008148 @default.
• W3136929667 hasConceptScore W3136929667C71924100 @default.
• W3136929667 hasIssue "4" @default.
• W3136929667 hasLocation W31369296671 @default.
• W3136929667 hasOpenAccess W3136929667 @default.
• W3136929667 hasPrimaryLocation W31369296671 @default.
• W3136929667 hasRelatedWork W2085558045 @default.
• W3136929667 hasRelatedWork W2162350346 @default.
• W3136929667 hasRelatedWork W2502853840 @default.
• W3136929667 hasRelatedWork W2946634840 @default.
• W3136929667 hasRelatedWork W3021226827 @default.
• W3136929667 hasRelatedWork W3138050359 @default.
• W3136929667 hasRelatedWork W3193040745 @default.
• W3136929667 hasRelatedWork W4210784828 @default.
• W3136929667 hasRelatedWork W6801340 @default.
• W3136929667 hasRelatedWork W59705712 @default.
• W3136929667 hasVolume "40" @default.
• W3136929667 isParatext "false" @default.
• W3136929667 isRetracted "false" @default.
• W3136929667 magId "3136929667" @default.
• W3136929667 workType "article" @default.